Oncology

Latest News

The investigators found that tumor mutational burden and PD-L1 expression, which have traditionally been used as indicators of immunotherapy efficacy, had little predictive value for survival in this cohort. | Image credit: Dragana Gordic - stock.adobe.com

Predictive Model Forecasts Advanced NSCLC Outcomes

By Jared Kaltwasser

August 14th 2025

The newly developed model has an area under the curve of 0.807 for predicting progression-free survival.

Dordaviprone is indicated for recurrent H3 K27M-mutant diffuse midline glioma, an ultra-rare, aggressive brain tumor primarily affecting children. | Image credit: wladimir1804 - stock.adobe.com

FDA Approves Dordaviprone as First and Only Treatment for Aggressive Form of Glioma

By Rose McNulty

August 6th 2025

Gen Li, PhD, MBA, president and founder of Phesi

Real-World Data, Digital Patient Profiles Are Revolutionizing Trial Design, Patient Recruitment: Gen Li, PhD, MBA

By Pearl Steinzor
Gen Li, PhD, MBA

August 4th 2025

Value-based care. | Image Credit: irissca - stock.adobe.com

Legal Navigation Services Key to Addressing Disparities in Cancer Care

By Cameron Santoro

July 31st 2025

Radiotherapy can work synergistically with immunotherapy by reprogramming the tumor microenvironment. | Image credit: Crystallight-stock.adobe.com

Brain Radiotherapy Plus ICIs Boost Survival in SCLC With Brain Metastases

By Jared Kaltwasser

July 30th 2025

Join this expert panel to discuss precision medicine in NSCLC, current immunotherapies, and more.

Watch the series now!

Watch Now

Join a panel of leaders as they discuss treatment for patients diagnosed with metastatic NSCLC without driver mutations

Continuing Medical Education

View All

August 17th 2025

The Economics of Transthyretin-Mediated Amyloidosis: Balancing Equity and Access in Resource Allocation

1 Credit / Cardiology, Neurology

August 17th 2025

Advancing Immunotherapy in Endometrial Cancer: A Managed Care Perspective on Personalized Care

1.5 Credits / Gynecologic Cancer, Health Equity, Diversity & Inclusion, Oncology, Women's Health

More News

November 21st 2014

Salk Scientists Want to Target the Protein Interactome for Drug Discovery

The study, published in Cell Reports, evaluates the dynamic protein interactions that promote different diseases including cancer. By capturing these interactions, the authors hope to discover new drug targets.

November 20th 2014

Large National Study Identifies Mastectomy Trend in Early Stage Disease

The retrospective study, published in JAMA Surgery, could not necessarily point to the underlying reason for this treatment choice.

November 20th 2014

IMS Report Estimates Over A Trillion Dollars in Drug Spending This Year

According to the report, sofosbuvir for hepatitis C infections and new cancer drugs were the drivers of the high spending costs, a 7% jump over the previous year.

November 19th 2014

The Argument For Better Patient-Centered Care in Oncology

Laura Joszt, MA

After 4 years of living with inflammatory breast cancer, Amy Berman, RN, BS, senior program officer at the John A. Hartford Foundation, she still felt fine, which she attributed to her care choices, she explained during her speech at The American Journal of Managed Care's Patient-Centered Oncology Care meeting in Baltimore, Maryland.

November 18th 2014

Study Identifies Disparities in Lung Cancer Treatment

The study, published in the Journal of Thoracic Oncology, identified race, insurance status, and the treatment center as variables that influenced treatment received by individuals with early-stage lung cancer.

November 18th 2014

ASCO Members Take a Stand on Access to Care for Low-Income Individuals

Surabhi Dangi-Garimella, PhD

In a paper published in the Journal of Clinical Oncology, medical oncologists have delineated their recommendations to improve cancer care and provide better access to quality care for those patients with financial issues and on Medicaid.

November 17th 2014

Dr Howard K. Kaufman Explains the Importance of Diagnostics on Precision Medicine

The evolving field of precision medicine is very much reliant on diagnostics, Howard K. Kaufman, MD, FACS, chief surgical officer and associate director for clinical science at Rutgers Cancer Institute of New Jersey, said at The American Journal of Managed Care's Patient-Centered Oncology Care meeting.

November 17th 2014

AJMC's Oncology Stakeholder Summit Participants Discuss Stringencies of Data Generation and Analysis

Surabhi Dangi-Garimella, PhD

November 17th 2014

Overuse of Imaging Adds $500 Million in Healthcare Costs, 500 More Cancer Cases a Year, Study Finds

Mary K. Caffrey

November 17th 2014

Tumor Treating Fields Can Halt Glioblastomas

An electrical device glued to the scalp can slow cancer growth and prolong survival in people with the deadliest type of brain tumor, researchers reported on Saturday in Miami, at a meeting of the Society for Neuro-Oncology.

November 17th 2014

Merck's Immuno-Oncology Molecule to Be Supported by Pfizer

The collaboration between the 2 drug giants will prove a big boost to Merck's cancer immunotherapy MSB0010718C, and will also improve it's global oncology business.

November 17th 2014

After Delays, Reimbursement Approvals Seen for Diagnostic Tests

Mary K. Caffrey

November 17th 2014

AJMC Panel Explores Immuno-oncology, and What Making Cancer a Chronic Condition Means for Payers

Mary K. Caffrey

November 17th 2014

Fertility Preservation in Young Cancer Patients

Surabhi Dangi-Garimella, PhD

November 17th 2014

Merck's Pembrolizumab: Breakthrough in NSCLC

Surabhi Dangi-Garimella, PhD

November 17th 2014

Panel Members Discuss Data Quality in Oncology Care

Surabhi Dangi-Garimella, PhD

November 17th 2014

The Challenge of Developing the Ideal Patient Satisfaction Survey

Betsy Chase Steven Dâ€™Amato, BSPharm, BCOP

November 17th 2014

The Debate on Treatment Options in Early-Stage Breast Cancer

Surabhi Dangi-Garimella, PhD

November 17th 2014

AJMC Oncology Conference Helps Managed Care Stakeholders Do More for Patients Who Have Coverage, But Still Have Limits

At its third annual conference, Patient-Centered Oncology Care 2014, The American Journal of Managed Care addressed new challenges in cancer care: more patients have coverage, but they may be "underinsured" or barred from academic centers. Amid rising drug costs and regulations that threaten community practices, the head of the largest oncology organization outlined a path toward value-based reimbursement.

November 17th 2014

Nivolumab Presents Superior Survival Results in Phase 3 Melanoma Trials

In a press release based off-of results presented at the Society for Melanoma Research 2014 International Congress in Zurich, Switzerland, BMS announced results from phase 3 of the CheckMate-066 trial.

November 16th 2014

A New Glioblastoma Vaccine on the Horizon

Following encouraging results from a second phase of a phase 1 trial, the researchers have planned a second phase, to be initiated in January 2015. The vaccine will be administered to glioblastoma patients just before they begin chemotherapy.

November 16th 2014

Long-term Results of Vismodegib in Patients With Basal Cell Carcinoma Reported

Final safety and efficacy results for vismodegib were reported at the Society for Melanoma Research, 2014 International Congress, for the 30-month mark of the ERIVANCE trial. The Congress is meeting November 13-16 in Zurich, Switzerland.

November 16th 2014

Oncolytic Virus Proves Promising in Advanced Melanoma

Despite the various treatment advances in melanoma, advanced stages of the disease remain a significant challenge for oncologists. Novel methods of attacking disease vulnerabilities continue to be developed-one such technique is the use of oncolytic viruses to destroy cancer cells. A couple of studies presented an update on preclinical and clinical progress with CAVATAK, formulated using the common cold Coxsackievirus Type A21 (CVA21), during the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13—16.

November 16th 2014

Vemurafenib Treatment Beyond Progression Is Safe and Highly Effective in Patients with Metastatic Melanoma

Patients with metastatic melanoma receiving vemurafenib following disease progression showed similar or better overall response to patients without progressive disease, according to findings from an analysis reported at the 11th International Congress of the Society for Melanoma Research on November 15, 2014.

November 16th 2014

More Good News on Pembrolizumab for Melanoma Patients Without Other Options

Results of a head-to-head comparison of pembrolizumab and standard chemotherapy in patients with advanced melanoma, including those who had experienced disease progression following ipilimumab, showed superior clinical response with pembrolizumab that was durable.

November 15th 2014

More Details Presented on Melanoma Diagnostic Test

Much of the news at the Society of Melanoma Research, 2014 International Congress, involves breakthrough therapies for treating metastatic melanoma in its later stages. But the year has brought developments in diagnostics, too. Tools to determine which patients need aggressive treatment and which ones do not are becoming important. As awareness of melanoma grows, more patients arrive at doctors' offices with suspicious skin marks at earlier stages.

November 15th 2014

Autophagy Regulators: An Emerging Target in Melanoma

During the first plenary session on the second day of the Society for Melanoma Research, 2014 International Congress in Zurich, Switzerland, November 13-16, Targeted Therapies: Genetics and Biology, several researchers presented their thoughts on where they see the future of melanoma research.

November 14th 2014

Integrating Palliative Care Into Managed Care for the Good of Patients

Mary K. Caffrey

Yesterday, speakers opened Patient-Centered Oncology Care, sponsored by The American Journal of Managed Care, with a discussion of how to bring palliative care into the mainstream in cancer care. While progress has been made, a cultural bias against discussion end-of-life issue remains an obstacle.

November 14th 2014

FDA Approves Avastin Plus Chemotherapy for Platinum-Resistant Ovarian Cancer

Genentech announced that Avastin has been approved to treated platinum-resistant ovarian cancer, inc combination with chemotherapy, which now expands Avastin's use to 6 tumor types.

November 14th 2014

Managed Care Audience Hears ASCO's Peter Yu, MD, Describe Value-Based Efforts

Mary K. Caffrey

Peter Yu, MD, president of the American Society of Clinical Oncology, (ASCO) discussed the organization's efforts throughout 2014 to reform reimbursement and take on issues of value and quality in cancer care during Patient-Centered Oncology Care, the annual gathering sponsored by The American Journal of Managed Care.

...

148 149 150 151 152 153 154 155 156

...

187 >

2 Commerce Drive
Suite 100
Cranbury, NJ 08512

Do Not Sell My Information

Terms & Conditions